iCo Therapeutics Announces Positive iCo-007 Phase 2 Clinical Update – Provides Additional Guidance on Study Timelines and Further Updates –

[at noodls] – January 3, 2013, Vancouver, Canada – iCo Therapeutics Inc. (iCo or the Company) (TSX-V: ICO), today announced that at the midpoint of its Phase 2 iDEAL study for the treatment of … more

View todays social media effects on ISIS

View the latest stocks trending across Twitter. Click to view dashboard

See who Isis is hiring next, click here to view